Müller, Nadja <br/><br/>
Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.  [electronic resource] 

 -  Journal of immunotherapy (Hagerstown, Md. : 1997)  Jun 2015 
 - 197-210 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1537-4513 
<br/><br/><label>Standard No.: </label>10.1097/CJI.0000000000000082  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Cell Line<br/>Cell- and Tissue-Based Therapy<br/>Chemokine CXCL12--biosynthesis<br/>Chemotaxis--genetics<br/>Cytotoxicity, Immunologic<br/>Disease Models, Animal<br/>Ectopic Gene Expression<br/>ErbB Receptors--immunology<br/>Female<br/>Gene Expression<br/>Gene Order<br/>Genetic Therapy<br/>Genetic Vectors--administration & dosage<br/>Glioblastoma--etiology<br/>Humans<br/>Immunotherapy<br/>Killer Cells, Natural--immunology<br/>Lentivirus--genetics<br/>Mice<br/>Receptors, Antigen, T-Cell--genetics<br/>Receptors, CXCR4--genetics<br/>Recombinant Fusion Proteins--genetics<br/>Transduction, Genetic<br/>Tumor Burden<br/>Xenograft Model Antitumor Assays